Making Cell and Gene Therapy Accessible for Medicaid Enrollees: White Paper
This white paper, from Manatt Health, identifies key barriers that can impede Medicaid patients' access to cell and gene therapies, and policy solutions to address those barriers at the state and federal levels.
Cell and gene therapies can slow, stop, or even reverse disease progression, achieving life-changing results for patients who previously had no hope of effective treatment. However, low-income people covered by the Medicaid program have reduced access to these transformative therapies in comparison to those covered by Medicare or commercial insurance, and face barriers at each step on the journey from diagnosis to treatment.
This paper identifies key barriers that can impede Medicaid patients’ access to CGTs, as well as policy solutions to address those barriers at the state and federal levels. To read the white paper and learn more, click this text.
